Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

A recent study suggests that liraglutide, a drug similar to Ozempic, may reduce migraine frequency in obese individuals with ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

The MHRA has revealed it's received more than 560 reports of acute pancreatitis in patients taking GLP-1 injections since ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.

Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...

Novo Nordisk just killed its deal with Hims & Hers. But Hims might come out stronger after this development. Read why the ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...